GlassScriptPhysician profile
Nathan Schmulewitz
NPI 1699733196
$1,992.14
in general payments reported to CMS, 2019-2025
19 companies · $1,165 in 2025
The $1,165 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $37.93 · 2023: $161 · 2024: $417 · 2025: $1,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $481.43 | 2019-2025 | Axios, Acquire, Cre Pro |
| Abbvie INC. | $294.68 | 2024-2025 | |
| Olympus America INC. | $194.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.03 | 2023-2025 | Gattex, Entyvio |
| Genzyme Corporation | $186.56 | 2025 | |
| Janssen Biotech, INC. | $156.47 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $128.57 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $47.95 | 2025 | Vegzelma |
| Qol Medical, LLC | $43.34 | 2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $41.41 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $41.00 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $37.20 | 2024 | |
| Merck Sharp & Dohme LLC | $33.13 | 2024 | Dificid |
| Ferring Pharmaceuticals INC. | $23.96 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $22.76 | 2025 | Zenpep |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $22.49 | 2025 | Iqirvo |
| Glaxosmithkline, LLC. | $17.11 | 2024 | Nucala |
| Intercept Pharmaceuticals, INC. | $15.42 | 2024 | |
| Gilead Sciences, INC. | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Schmulewitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.